Medtronic Ardian Luxembourg S.a.r.l.

Medtronic Vascular, Inc.

Medtronic Ireland Manufacturing Unlimited Company

Medtronic Adrian Luxembourg S.a.r.l.

Ayala Hezi-Yamit

Carol M Sullivan

Susan Edwards

Christopher W Storment

Rudy Beasley

Michele Lee Silver

Stefan Stoyanov Tunev

Lori Garcia

Joseph A Traina

Mingfei Chen

Neil Chand Barman

Joseph Berglund

Robert Melder

Carol Sullivan

Stefan Tunev

Methods for treating a patient using therapeutic renal neuromodulation and associated devices, systems, and methods are disclosed herein. One aspect of the present technology is directed to biomarker sampling in the context of neuromodulation devices, systems, and methods. Some embodiments, for example, are directed to catheters, catheter systems, and methods for sampling biomarkers that change in response to neuromodulation. A system can include, for example, an elongated shaft and a neuromodulation and sampling assembly having a neuromodulation and a sampling element.

Biomarker sampling in the context of neuromodulation devices, systems, and methods

Provided herein are methods, systems, and devices for increasing heat shock protein expression and treating conditions for which increased heat shock protein expression is expected to be beneficial using thermal ablation.

Methods and devices for localized disease treatment by ablation

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. One aspect includes a comparison of baseline and post-modulation levels of one or more biomarkers in bodily fluid that have each been collected from a human subject at a relevant time, and that may be used to assess the neuromodulation efficacy. The post-neuromodulation levels for the one or more biomarkers may be collected from the human subject within about 5 minutes to about 14 days post-neuromodulation.

Monitoring of neuromodulation using biomarkers

Methods for treating gastrointestinal conditions, conditions associated with sympathetic and/or parasympathetic activity in the gastrointestinal organs, and conditions associated with central sympathetic and/or parasympathetic activity in a patient with therapeutic gastrointestinalneuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a gastrointestinal artery of a gastrointestinal organ of a patient. Sympathetic drive in the patient can thereby be reduced in a manner that treats the patient for the gastrointestinal condition.

Gastrointestinal neuromodulation and associated systems and methods

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers.

Devices and associated methods for monitoring of neuromodulation using biomarkers

Provided herein are methods, systems, and devices for increasing IL-10 expression, inhibiting inflammation, and treating inflammatory conditions using thermal ablation.

Methods and devices for localized inhibition of inflammation by ablation

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on detecting changes in the level or activity of one or more target biomarkers associated with neuromodulation, as well as methods and processes of performing neuromodulation that incorporate monitoring of neuromodulation efficacy based on changes in level or activity of one or more target biomarkers.

Devices and methods for therapeutic photodynamic modulation of neural function in a human. One embodiment of a method in accordance with the technology includes administering a photosensitizer to a human, wherein the photosensitizer preferentially accumulates at nerves proximate a blood vessel compared to non-neural tissue of the blood vessel. The method can further include irradiating the photosensitizer using a radiation emitter positioned within the human, wherein the radiation has a wavelength that causes the photosensitizer to react and alter at least a portion of the nerves thereby providing a therapeutic reduction in sympathetic neural activity. Several embodiments of the technology are useful for disrupting renal nerves, such as renal denervation, for treating hypertension, diabetes, congestive heart failure, and other indications.

Devices and methods for photodynamically modulating neural function in a human

Described herein are nitric oxide (NO)-donating poly(tetrafluoroethylene) (PTFE) polymers and polymer surfaces and methods of making and using the same. The NO-donating PTFE polymers can be used to fabricate at least a portion of an implantable medical device, coat at least a portion of an implantable medical device or form at least a portion of an implantable medical device. The NO-donating PTFE polymers provide controlled release of NO once implanted at or within the target site.

Poly(tetrafluoroethylene) polymer with nitric oxide donating surface

The present disclosure relates to devices methods for the reverse transport of lipids such as cholesterols for the treatment diseases and conditions caused by vulnerable plaques. The devices can reduce or eliminate vulnerable plaques by transporting the plaques away from their location.

Growing community of inventors

Santa Rosa, CA, United States of America

Ayala Hezi-Yamit